Combination Therapy for BRAF-V600E Metastatic CRCm

The BRAVE is a phase II clinical trial aimed at evaluating the efficacy of the combination therapy of encorafenib, cetuximab, and bevacizumab in patients with metastatic colorectal cancer (CRC) harboring the BRAF-V600E mutation. This mutation is present in about 8-10% of CRC cases and is associated with poor prognosis and limited treatment options. The rationale behind this trial stems from preclinical studies suggesting that the overexpression and activation of vascular endothelial growth factor A (VEGFA) may contribute to resistance to BRAF inhibitors (BRAFi) in CRC. Thus, the trial hypothes

Trial Details

NCT ID
NCT06411600
Phase
PHASE2
Sponsor
Vall d'Hebron Institute of Oncology
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Encorafenib
  • Cetuximab
  • Bevacizumab
Locations (sample)
  • Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Provision of signed and dated informed consent form.
  • Age ≥18 years at time of informed consent.
  • Histologically- or cytologically-confirmed mCRC that is metastatic.
  • Presence of BRAF V600E mutation in tumor tissue previously determined according to the guidelines of each center, any time point before the enrollm…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →